CAR T-Cell Immunotherapy Market by Type and Indication- Global Industry Analysis & Forecast to 2027
Published On : January 2021 Pages : 158 Category: Equipment Machine & Tooling Report Code : ME0114590
CAR T-Cell Immunotherapy Market By Type (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The CAR T-Cell Immunotherapy Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.CAR T-Cell Immunotherapy is mainly used for thetreatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.CAR T cells and other ACT approaches has greatly accelerated, with researchers developing a better understanding of how these therapies work in patients and translating that knowledge into improvements in how they are developed and tested.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global CAR T-Cell Immunotherapy Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Bluebird Bio (US)
- Celgene Corporation (US)
- Gilead Sciences, Inc. (US)
- Cellectis (France)
- Servier Laboratories (France)
- Pfizer Inc. (US)
- MereckKGaA (Germany)
- Amgen Inc. (US)
- Intellia Therapeutics (US)
- Novartis International AG (Swiss),
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· CAR T-Cell Immunotherapy Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o CD19/CD22
o BCMA
o Others
· CAR T-Cell Immunotherapy Market, ByIndication, Estimates and Forecast, 2017-2027 ($Million)
o Diffuse Large B-Cell Lymphoma (DLBCL)
o Acute Lymphoblastic Leukemia (ALL)
o Chronic Lymphocytic Leukemia (CLL)
o Multiple Myeloma (MM)
o Follicular Lymphoma (FL)
o Others
· CAR T-Cell Immunotherapy Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Bluebird Bio (US)
o Celgene Corporation (US)
o Gilead Sciences, Inc. (US)
o Cellectis (France)
o Servier Laboratories (France)
o Pfizer Inc. (US)
o MereckKGaA (Germany)
o Amgen Inc. (US)
o Intellia Therapeutics (US)
o Novartis International AG (Swiss)
· CAR T-Cell Immunotherapy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America CAR T-Cell Immunotherapy Market, By Country
o U.S. CAR T-Cell Immunotherapy Market
o Canada CAR T-Cell Immunotherapy Market
o Mexico CAR T-Cell Immunotherapy Market
o Europe
§ Europe CAR T-Cell Immunotherapy Market, By Country
o UK CAR T-Cell Immunotherapy Market
o Germany CAR T-Cell Immunotherapy Market
o France CAR T-Cell Immunotherapy Market
o Russia CAR T-Cell Immunotherapy Market
o Italy CAR T-Cell Immunotherapy Market
o Rest of Europe CAR T-Cell Immunotherapy Market
o Asia-Pacific
§ Asia-Pacific CAR T-Cell Immunotherapy Market, By Country
o China CAR T-Cell Immunotherapy Market
o Japan CAR T-Cell Immunotherapy Market
o South Korea CAR T-Cell Immunotherapy Market
o India CAR T-Cell Immunotherapy Market
o Southeast Asia CAR T-Cell Immunotherapy Market
o Rest of Asia-Pacific CAR T-Cell Immunotherapy Market
o South America
§ South America CAR T-Cell Immunotherapy Market
o Brazil CAR T-Cell Immunotherapy Market
o Argentina CAR T-Cell Immunotherapy Market
o Columbia CAR T-Cell Immunotherapy Market
o Rest of South America CAR T-Cell Immunotherapy Market
o Middle East and Africa
§ Middle East and Africa CAR T-Cell Immunotherapy Market
o Saudi Arabia CAR T-Cell Immunotherapy Market
o UAE CAR T-Cell Immunotherapy Market
o Egypt CAR T-Cell Immunotherapy Market
o Nigeria CAR T-Cell Immunotherapy Market
o South Africa CAR T-Cell Immunotherapy Market
o TurkeyCAR T-Cell Immunotherapy Market
o Rest of MEA CAR T-Cell Immunotherapy Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. CAR T-Cell Immunotherapy Market, By Type
5.1. Introduction
5.2. Global CAR T-Cell Immunotherapy Revenue and Market Share by Type (2017-2021)
5.2.1. Global CAR T-Cell Immunotherapy Revenue and Revenue Share by Type (2017-2021)
5.3. CD19/CD22
5.3.1. Global CD19/CD22 Revenue and Growth Rate (2017-2021)
5.4. BCMA
5.4.1. Global BCMA Revenue and Growth Rate (2017-2021)
5.5. Others
5.5.1. Global Others Revenue and Growth Rate (2017-2021)
6. CAR T-Cell Immunotherapy Market, By Indication
6.1. Introduction
6.2. Global CAR T-Cell Immunotherapy Revenue and Market Share by Indication (2017-2021)
6.2.1. Global CAR T-Cell Immunotherapy Revenue and Revenue Share by Indication (2017-2021)
6.3. Diffuse Large B-Cell Lymphoma (DLBCL)
6.3.1. Global Diffuse Large B-Cell Lymphoma (DLBCL) Revenue and Growth Rate (2017-2021)
6.4. Acute Lymphoblastic Leukemia (ALL)
6.4.1. Global Acute Lymphoblastic Leukemia (ALL) Revenue and Growth Rate (2017-2021)
6.5. Chronic Lymphocytic Leukemia (CLL)
6.5.1. Global Chronic Lymphocytic Leukemia (CLL) Revenue and Growth Rate (2017-2021)
6.6. Multiple Myeloma (MM)
6.6.1. Global Multiple Myeloma (MM) Revenue and Growth Rate (2017-2021)
6.7. Follicular Lymphoma (FL)
6.7.1. Global Follicular Lymphoma (FL) Revenue and Growth Rate (2017-2021)
6.8. Others
6.8.1. Global Others Revenue and Growth Rate (2017-2021)
7. CAR T-Cell Immunotherapy Market, By Region
7.1. Introduction
7.2. Global CAR T-Cell Immunotherapy Revenue and Market Share by Regions
7.2.1. Global CAR T-Cell Immunotherapy Revenue by Regions (2017-2021)
7.3. North America CAR T-Cell Immunotherapy by Countries
7.3.1. North America CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2021)
7.3.2. North America CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe CAR T-Cell Immunotherapy by Countries
7.4.1. Europe CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2021)
7.4.2. Europe CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific CAR T-Cell Immunotherapy by Countries
7.5.1. Asia-Pacific CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America CAR T-Cell Immunotherapy by Countries
7.6.1. South America CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2021)
7.6.2. South America CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa CAR T-Cell Immunotherapy by Countries
7.7.1. Middle East and Africa CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Bluebird Bio (US)
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Celgene Corporation (US)
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Gilead Sciences, Inc. (US)
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Cellectis (France)
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Servier Laboratories (France)
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Pfizer Inc. (US)
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Mereck KGaA (Germany)
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Amgen Inc. (US)
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Intellia Therapeutics (US)
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Novartis International AG (Swiss)
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.1. Global CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. CAR T-Cell Immunotherapy Market Forecast by Regions (2022-2027)
9.2.1. North America CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.1.1. United States CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.1.2. Canada CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.1.3. Mexico CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2. Europe CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.1. Germany CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.2. France CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.3. UK CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.4. Russia CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.5. Italy CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.2.6. Rest of Europe CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3. Asia-Pacific CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.1. China CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.2. Japan CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.3. Korea CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.4. India CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.5. Southeast Asia CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.4. South America CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.4.1. Brazil CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.4.2. Argentina CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.4.3. Columbia CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.4.4. Rest of South America CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5. Middle East and Africa CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.3. Egypt CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.4. Nigeria CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.5. South Africa CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.6. Turkey CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa CAR T-Cell Immunotherapy Market Forecast (2022-2027)
9.3. CAR T-Cell Immunotherapy Market Forecast by Type (2022-2027)
9.3.1. CAR T-Cell Immunotherapy Forecast by Type (2022-2027)
9.3.2. CAR T-Cell Immunotherapy Market Share Forecast by Type (2022-2027)
9.4. CAR T-Cell Immunotherapy Market Forecast by Indication (2022-2027)
9.4.1. CAR T-Cell Immunotherapy Forecast by Indication (2022-2027)
9.4.2. CAR T-Cell Immunotherapy Market Share Forecast by Indication (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure France CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure China CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure India CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa CAR T-Cell Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Table Global CAR T-Cell Immunotherapy Revenue and Revenue Share by Type (2017-2019)
Figure Global CD19/CD22 Revenue and Growth Rate (2017-2019)
Figure Global BCMA Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global CAR T-Cell Immunotherapy Revenue and Revenue Share by Indication (2017-2019)
Figure Global Diffuse Large B-Cell Lymphoma (DLBCL) Revenue and Growth Rate (2017-2019)
Figure Global Acute Lymphoblastic Leukemia (ALL) Revenue and Growth Rate (2017-2019)
Figure Global Chronic Lymphocytic Leukemia (CLL) Revenue and Growth Rate (2017-2019)
Figure Global Multiple Myeloma (MM) Revenue and Growth Rate (2017-2019)
Figure Global Follicular Lymphoma (FL) Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global CAR T-Cell Immunotherapy Revenue by Regions (2017-2019)
Figure North America CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure North America CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2019)
Figure North America CAR T-Cell Immunotherapy by Countries (2017-2019)
Figure North America CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure United States CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure United States CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Canada CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Mexico CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Europe CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Europe CAR T-Cell Immunotherapy by Countries (2017-2019)
Figure Europe CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Germany CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Germany CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure France CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure UK CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Russia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Italy CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Rest of Europe CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Asia-Pacific CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific CAR T-Cell Immunotherapy by Countries (2017-2019)
Figure Asia-Pacific CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure China CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure China CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Japan CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Korea CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure India CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Southeast Asia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Rest of Asia-Pacific CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure South America CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2019)
Figure South America CAR T-Cell Immunotherapy by Countries (2017-2019)
Figure South America CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Brazil CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Brazil CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Argentina CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Columbia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Rest of South America CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Middle East and Africa CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa CAR T-Cell Immunotherapy by Countries (2017-2019)
Figure Middle East and Africa CAR T-Cell Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Saudi Arabia CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure United Arab Emirates CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Egypt CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Nigeria CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure South Africa CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Turkey CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa CAR T-Cell Immunotherapy Growth Rate (2017-2019)
Figure Rest of Middle East and Africa CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Table Bluebird Bio (US) CAR T-Cell Immunotherapy Financial Overview
Table Celgene Corporation (US) CAR T-Cell Immunotherapy Financial Overview
Table Gilead Sciences, Inc. (US) CAR T-Cell Immunotherapy Financial Overview
Table Cellectis (France) CAR T-Cell Immunotherapy Financial Overview
Table Servier Laboratories (France) CAR T-Cell Immunotherapy Financial Overview
Table Pfizer Inc. (US) CAR T-Cell Immunotherapy Financial Overview
Table Mereck KGaA (Germany) CAR T-Cell Immunotherapy Financial Overview
Table Amgen Inc. (US) CAR T-Cell Immunotherapy Financial Overview
Table Intellia Therapeutics (US) CAR T-Cell Immunotherapy Financial Overview
Table Novartis International AG (Swiss) CAR T-Cell Immunotherapy Financial Overview
Figure Global CAR T-Cell Immunotherapy Revenue (Millions USD) and Growth Rate (2019-2027)
Table CAR T-Cell Immunotherapy Market Forecast by Regions (2019-2027)
Figure North America CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure United States CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Canada CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Mexico CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Europe CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Germany CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure France CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure UK CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Russia CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Italy CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Rest of Europe CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Asia-Pacific CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure China CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Japan CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Korea CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure India CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Southeast Asia CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Rest of Asia-Pacific CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure South America CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Brazil CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Argentina CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Columbia CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Rest of South America CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Middle East and Africa CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Saudi Arabia CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure United Arab Emirates CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Egypt CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Nigeria CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure South Africa CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Turkey CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Rest of Middle East and Africa CAR T-Cell Immunotherapy Market Forecast (2019-2027)
Figure Global CAR T-Cell Immunotherapy Forecast by Type (2019-2027)
Figure Global CAR T-Cell Immunotherapy Market Share Forecast by Type (2019-2027)
Figure Global CAR T-Cell Immunotherapy Forecast by Type (2019-2027)
Figure Global CAR T-Cell Immunotherapy Forecast by Indication (2019-2027)
Figure Global CAR T-Cell Immunotherapy Market Share Forecast by Indication (2019-2027)
Figure Global CAR T-Cell Immunotherapy Forecast by Indication (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|